Black Diamond Therapeutics Q4 2019 Earnings Report
Key Takeaways
Black Diamond Therapeutics reported its Q4 and full year 2019 financial results. The FDA allowed the IND application for BDTX-189, and the company initiated a Phase 1/2 clinical trial. Black Diamond believes that the $316 million raised since November, including via its IPO, will enable them to execute the clinical development of BDTX-189, continue to invest in their MAP platform, and progress their early stage pipeline.
FDA allowed the IND application for BDTX-189 in December and initiated Phase 1/2 clinical trial
Company started enrolling and dosing patients in Phase 1/2 clinical trial
Cash and cash equivalents of $154.7 million as of December 31, 2019
Completed IPO in February 2020 raised approximately $231.3 million in gross proceeds
Black Diamond Therapeutics
Black Diamond Therapeutics
Forward Guidance
The company did not provide specific financial guidance for future periods.